Compare AbbVie Inc (ABBV) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VanEck Semiconductor ETF — how do they compare? AbbVie Inc trades at $253.24 (market cap $449.91B), while VanEck Semiconductor ETF trades at $589.95. The key difference: AbbVie Inc pays a 2.72% dividend while VanEck Semiconductor ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | SMH | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $668.91 |
52-Week Low | $184.85 | $283.48 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
SMH trades at $581.45, down 1.83% amid a semiconductor sector sell-off. Technical indicators show a neutral bias with mixed moving averages and oscillators, while support and resistance levels suggest consolidation near $609 pivot. Recent news highlights chip stock volatility, with JPMorgan advising to buy the dip despite hedge fund outflows. The ETF remains a high-beta play on AI-driven semiconductor demand, though financial ratios are unavailable for valuation context.
Outlook hinges on AI capex cycles and memory chip shortages, but risks include sector rotation and earnings pressure. Institutional sentiment is cautious despite long-term growth themes, with technicals indicating near-term range-bound action. Investors face volatility from hyperscaler shifts and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
